[1] H. Q. Wang, W. Di Zhang, B. Yuan, and J. B. Zhang, (2021) “Advances in the regulation of mammalian follicle-stimulating hormone secretion,” Animals, vol. 11, no. 4https://doi.org/10.3390/ani11041134
[2] D. Horgan et al., (2022) “Tackling Thyroid Cancer in Europe—The Challenges and Opportunities,” Healthc., vol. 10, no. 9, pp. 1–13.
[3] L. Chaker, A. C. Bianco, J. Jonklaas, and R. P. Peeters, (2017) “Hypothyroidism,” Lancet, vol. 390, no. 10101, pp. 1550–1562. https://doi.org/10.1016/s0140-6736(17)30703-1
[4] J. R. Stockigt, “Free thyroid hormone measurement: A critical appraisal, (2001)” Endocrinol. Metab. Clin. North Am., vol. 30, no. 2, pp. 265–289. https://doi.org/10.1016/s0889-8529(05)70187-0
[5] R. Wang, J. C. Nelson, R. M. Weiss, and R. B. Wilcox, (2000) “Accuracy of free thyroxine measurements across natural ranges of thyroxine binding to serum proteins,” Thyroid, vol. 10, no. 1, pp. 31–39.
[6] M. S. Byerly et al., (2013) “Identification of hypothalamic neuron-derived neurotrophic factor as a novel factor modulating appetite,” Am. J. Physiol. - Regul. Integr. Comp. Physiol., vol. 304, no. 12, pp. 1085–1095. https://doi.org/10.1152%2Fajpregu.00368.2012
[7] H. Y. Yasar, M. Demirpence, A. Colak, M. Zeytinli, E. Yasar, and A. Taylan, (2022) “Serum neudesin levels in patients with polycystic ovary syndrome,” Ginekol. Pol., vol. 93, no. 7, pp. 525–530.
[8] A. Polkowska, I. E. Pasierowska, M. Pasławska, E. Pawluczuk, and A. Bossowski, (2019) “Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes,” Biomed Res. Int., vol. 2019, p. 6. https://doi.org/10.1155/2019/6128410
[9] E. Ç. Eren, S. Kaya, and D. Argun, (2022) “The assessment of maternal and umbilical cord neudesin levels in pregnancies with gestational diabetes mellitus,” J. Obstet. Gynaecol. (Lahore)., vol. 42, no. 7, pp. 2941–2945. http://dx.doi.org/10.3390/ijerph19063684
[10] G. J. Canaris, N. R. Manowitz, G. Mayor, and E. C. Ridgway, (2000) “The colorado thyroid disease prevalence study,” Arch. Intern. Med., vol. 160, no. 4, pp. 526–534. https://doi.org/10.1001/archinte.160.4.526
[11] L. H. Duntas, (2002) “Thyroid disease and lipids,” Thyroid, vol. 12, no. 4, pp. 287–293. https://doi.org/10.1089/10507250252949405
[12] D. V. Kumar, D. S. L. Mathur, and D. R. K. Tuteja, (2019) “Effects of Thyroid Dysfunction on Lipid Profile,” Int. J. Med. Biomed. Stud., vol. 3, no. 6, pp. 76–84.
[13] S. F. Tuleab Alaaraji, (2019) “Exploration of the Relationship between Interleukins 17, 37 and 38 with Vitamin E in Iraqi Men with CHB,” J. Phys. Conf. Ser., vol. 1294, no. 5.
[14] K. F. Al-Rawi et al., (2022) “Relationship Between IL-2, IL-17 Concentrations, and Serum Creatinine Levels in Men with Chronic Kidney Diseases,” Reports Biochem. Mol. Biol., vol. 10, no. 4, pp. 664–674.
[15] T. V. T. Tran, C. M. Kitahara, F. de Vathaire, M. C. Boutron-Ruault, and N. Journy, (2020) “Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis,” Endocr. Relat. Cancer, vol. 27, no. 4, pp. 245–249.
[16] H. Münzberg and L. Receptor, (2010) “Leptin-Signaling Pathways and Leptin Resistance Leptin Action in the Central Nervous System,” vol. 63, pp. 123–132. https://doi.org/10.1159/000264400
[17] S. A. W. A.-S. Abdul Hadeel, (2022) “Neudesin Levels in Patients with Thyroidism,” Egypt. J. Hosp. Med., vol. 89, no. October, pp. 7809–7813.
[18] G. Bozkaya, O. Fenercioglu, İ. Demir, A. Guler, B. Aslanipour, and M. Calan, (2020) “Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome,” Gynecol. Endocrinol., vol. 36, no. 10, pp. 849–853.
[19] E. Vergani, C. Bruno, C. Cipolla, D. Currò, and A. Mancini, (2022) “Plasma Levels of Neudesin and Glucose Metabolism in Obese and Overweight Children,” Front. Endocrinol. (Lausanne)., vol. 13, no. July, pp. 1–7. https://doi.org/10.3389/fendo.2022.881524
[20] T. Friis and L. R. Pedersen, (1987) “Serum lipids in hyper- and hypothyroidism before and after treatment,” Clin. Chim. Acta, vol. 162, no. 2, pp. 155–163.
)
